Interesting ImagesPharmacokinetic Analysis of [18F]FAZA Dynamic PET Imaging Acquisitions for Highlighting Sacrum Tumor ProfilesProvost, Claire PhD∗,†; Mammar, Hamid MD‡; Belly-Poinsignon, Anne PhD∗; Madar, Olivier PharmD†; Champion, Laurence MD∗Author Information From the ∗Department of Medical Imaging, Nuclear Medicine, Institut Curie, Saint-Cloud †Department of Radio-pharmacology, Institut Curie, Saint-Cloud ‡Department of Radio-therapy, Institut Curie, Orsay, France. Received for publication April 1, 2019; revision accepted August 5, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Claire Provost, PhD, Department of Nuclear Medicine and Radio-pharmacology, Institut Curie, 35 rue Dailly, 92210 Saint-Cloud, France. E-mail: [email protected]. Clinical Nuclear Medicine: January 2020 - Volume 45 - Issue 1 - p e36-e38 doi: 10.1097/RLU.0000000000002813 Buy Metrics Abstract A patient enrolled in a clinical trial (NCT02802969) with suspicion of chordoma underwent an [18F]FAZA PET/CT, a radiolabeled nitroimidazole analog of hypoxia PET imaging. The patient's images showed a different tumor profile compared to those observed in other hypoxic or nonhypoxic chordoma patients. The motivation for using [18F]FAZA pharmacokinetic imaging was to compare this profile with histologically confirmed cases of chordoma. Through visual imaging and quantification of blood and tumor time-activity curves, we excluded the hypothesis that it was a chordoma, diagnosing a paraganglioma. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.